Study on database of 41 stage IIIb/IV non-small cell lung cancer (NSCLC) patients treated by chemoregimen Vinorelbine+Cisplatin at K hospital from October 2008 to October 2012. Results: Average age was 56,12 percent 8,6. Age above 50 was the most common group (78,0 percent). Male/female ration was 2,42/1. The patients came to the hospital lately 3-6 months after the first symptoms accounted for 68,3 percent. 63,4 percent patients had Kamofski or = 80 percent. Stage IV were more common than stage IIIb (39 percent vs 61 percent). High CEA level appeared in 73,2 percent, highest 1000ng/ml. Total chemo-cycles had been underwent for 41 patients was 178. Patients completed 3 or 6 cycles with the rates were 46,3 percent and 36,6 percent
respectively. 75,6 percent patients had improved clinical symptoms, 17,1 percent had complete response clinically (no sympotms). There was no complete response objectively. Partial response accounted for 29,3 percent. Stable disease and Progession disease accounted for 70,8 percent. Stage IIIb had better response than stage IV. The difference was statistically with p 0,05. Patients who underwent 6 cycles had statistically significant lower response rates than patients completed 6 cycles (11,5 percent & 60,0 percent), with P